Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

NewBiotics

company

About

NewBiotics' strategy is to transform drug resistance into therapeutic advantage.

  • 11 - 50

Details

Last Funding Type
Series C
Last Funding Money Raised
$11M
Industries
Health Care,Medical,Therapeutics
Founded date
Sep 1, 1997
Number Of Employee
11 - 50
Operating Status
Active

NewBiotics transforms drug resistances into therapeutic advantages. It focuses on the discovery and development of drug molecules that leverage the cycle of drug resistance in both cancer and infectious diseases.

NewBiotics is a U.S.-based company that was founded in 1997 and the company was acquired by Celmed Biosciences on June 7, 2004.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$21.87M
NewBiotics has raised a total of $21.87M in funding over 2 rounds. Their latest funding was raised on Apr 27, 2004 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 27, 2004 Series E $4.57M 1 Detail
Jul 25, 2001 Series C $11M 3 Detail
Apr 4, 2000 Series Unknown $6.30M 1 Inglewood Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
3
NewBiotics is funded by 3 investors. Inglewood Ventures and Cheng Xin Technology Development Corp are the most recent investors.
Investor Name Lead Investor Funding Round
Inglewood Ventures Series E
Cheng Xin Technology Development Corp Series C
FAT Capital Series C